Abbott Laboratories logo

Abbott Laboratories (ABT)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
104. 88
+0.2
+0.1911%
$
172.35B Market Cap
36.49 P/E Ratio
0.28% Div Yield
7.95M Volume
4.44 Eps
$ 104.68
Previous Close
Add Transaction
Day Range
104.19 105.88
Year Range
81.97 132.03
Want to track ABT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Abbott (ABT) Dips More Than Broader Market: What You Should Know

Abbott (ABT) Dips More Than Broader Market: What You Should Know

In the most recent trading session, Abbott (ABT) closed at $89.17, indicating a -2.28% shift from the previous trading day.

Zacks | 4 months ago
Mounting Evidence Backs Abbott's Cancer Diagnostics Growth Story

Mounting Evidence Backs Abbott's Cancer Diagnostics Growth Story

ABT's Exact Sciences acquisition expands its cancer diagnostics portfolio as new data and screening guidelines strengthen growth prospects.

Zacks | 4 months ago
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 4 months ago
Baron Discovery Fund Q1 2026: Who Moved The Needle

Baron Discovery Fund Q1 2026: Who Moved The Needle

In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing the Russell 2000 Growth Index by 7.84% due to significant underperformance in the software sector. Advanced Energy Industries, Inc.'s stock rose during the quarter as the market began to appreciate the strength that the company would see in both its data center and semiconductor end markets. Baron Discovery Fund sold its investment in Intapp, Inc. in the quarter as the team believes that its other software holdings have better overall competitive advantages.

Seekingalpha | 4 months ago
Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock

Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock

ABT wins CE Mark for Libre Duo systems, the first dual glucose-ketone sensors, enabling real-time monitoring as European rollout begins later this year.

Zacks | 4 months ago
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Zacks | 4 months ago
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?

Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks | 4 months ago
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know

Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know

Abbott (ABT) concluded the recent trading session at $85.68, signifying a -1.14% move from its prior day's close.

Zacks | 4 months ago
Silver Economy Investing: Why the Healthcare Giants Are in Focus

Silver Economy Investing: Why the Healthcare Giants Are in Focus

Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.

Zacks | 5 months ago
The Dip That Keeps On Dipping: 2 Strong Buy Stocks Near 52-Week Lows With 50%+ Upside Potential

The Dip That Keeps On Dipping: 2 Strong Buy Stocks Near 52-Week Lows With 50%+ Upside Potential

Build-A-Bear Workshop and Abbott Laboratories are compelling dividend stocks, each trading near lows with yields close to 3%. BBW offers a debt-free balance sheet, aggressive share repurchases, and international expansion, positioning for 9.3% earnings CAGR and over 70% upside to its $62 target. ABT, trading at a forward P/E of 15.31x, is undervalued with robust liquidity, ongoing buybacks, and insider buying, despite segment weakness and lowered guidance.

Seekingalpha | 5 months ago
Boston Scientific Bets on Growth Through Strategic M&A Deals

Boston Scientific Bets on Growth Through Strategic M&A Deals

BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.

Zacks | 5 months ago
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?

ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?

Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.

Zacks | 5 months ago
Loading...
Load More